Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727972 | 0.94 | HRH3 (0.67) | HRH3CYP3A4KCNH2MEN1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL1728065 | 0.90 | HRH3 (0.64) | HRH3CYP3A4KCNH2 | |
| SCHEMBL1729698 | 0.83 | HRH3 (0.70) | HRH3CYP3A4MEN1ALDH1A1MAPT | |
| Trifluoroacetic Acid SCHEMBL1727989 | 0.83 | HRH3 (0.87) | HRH3CYP3A4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2994664 | 0.80 | HRH3 (0.87) | HRH3CYP3A4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL223740 | 0.80 | HRH3 (0.65) | HRH3CYP3A4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2423337 | 0.79 | HRH3 (0.65) | HRH3KCNH2MAPT | |
| Trifluoroacetic Acid SCHEMBL1728317 | 0.79 | HRH3 (0.86) | HRH3CYP3A4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2426736 | 0.79 | HRH3 (0.62) | HRH3KCNH2MEN1ALDH1A1MAPT | |
| SCHEMBL10819842 | 0.78 | HRH3 (0.67) | HRH3CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222290-B2 | Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof | SANOFI (FR) | 2012-07-17 | — | — | US | disclosed |
| EP-2215058-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-11-23 | — | — | EP | disclosed |
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | HRH3, HRH4, UTS2R | HRH3 1/4885CYP3A4 737/4885KCNH2 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.